OpGen, Inc., a Gaithersburg, Maryland-based commercial phase genomics company, completed a $17m Series B equity financing.
The round was led by jVen Capital, with participation from other existing investors, including CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical and Versant Ventures.
In conjunction with the financing, Evan Jones, managing member of jVen Capital, will lead OpGen’s board of directors as executive chairman. Mr. Jones was previously a board member and also served as interim CEO of the company.
As also stated by Douglas White, CEO of OpGen, this financing will support the marketing efforts for theArgus™ Optical Mapping System, which was commercially launched in June 2010 to investigate microbial structure, function, diversity and genetics.
In addition, the capital will accelerate the company’s initiatives to expand into new markets, including the development of new applications that will complement sequencing technologies and help facilitate completion of large genome mapping and finishing technologies currently under development at the company.